New advances on prostate carcinogenesis and therapies:: Involvement of EGF-EGFR transduction system

被引:40
作者
Mimeault, M [1 ]
Pommery, N [1 ]
Hénichart, JP [1 ]
机构
[1] Fac Pharm, Inst Chim Pharmaceut Albert Lespagnol, F-59006 Lille, France
关键词
prostate carcinogenesis; EGF-EGFR system; tumor growth and metastasis; apoptotic death; anticarcinogenic therapies;
D O I
10.1080/0897719031000094921
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The prostate cancers (PCs) are among the major causes of death because therapeutic treatments are not effective against advanced and metastatic forms of this cellular hyperproliferative disorder. In fact, although androgen-deprivation therapies permit to cure localized PC forms, the metastatic PC cells have acquired multiple functional features that confer to them resistance to ionizing radiations and anticarcinogenic drugs currently used in therapy. The present review describes last advances on molecular mechanisms that might be responsible for sustained growth and survival of PC cells. In particular, emphasis is on intracellular signaling cascades which are involved in the mitogenic and antiapoptotic effects of epidermal growth factor EGF-EGFR system. Of therapeutic interest, recent advances and prospects for development of new treatments against incurable forms of metastatic PC forms are also discussed.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 173 条
[1]   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].
Albanell, J ;
Rojo, F ;
Averbuch, S ;
Feyereislova, A ;
Mascaro, JM ;
Herbst, R ;
LoRusso, P ;
Rischin, D ;
Sauleda, S ;
Gee, J ;
Nicholson, RI ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124
[2]   Protein kinase A-Iα subunit-directed antisense inhibition of ovarian cancer cell growth:: crosstalk with tyrosine kinase signaling pathway [J].
Alper, Ö ;
Hacker, NF ;
Cho-Chung, YS .
ONCOGENE, 1999, 18 (35) :4999-5004
[3]   The caveolae membrane system [J].
Anderson, RGW .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :199-225
[4]   Androgen deprivation as a strategy for prostate cancer chemoprevention [J].
Aquilina, JW ;
Lipsky, JJ ;
Bostwick, DG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10) :689-696
[5]  
Attiga FA, 2000, CANCER RES, V60, P4629
[6]   COX-2 and cancer: a new approach to an old problem [J].
Bakhle, YS .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) :1137-1150
[7]   Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes [J].
Banerjee, PP ;
Banerjee, S ;
Brown, TR .
ENDOCRINOLOGY, 2002, 143 (05) :1825-1832
[8]   Bradykinin induced mitogenesis of androgen independent prostate cancer cells [J].
Barki-Harrington, L ;
Daaka, Y .
JOURNAL OF UROLOGY, 2001, 165 (06) :2121-2125
[9]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[10]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302